Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TRAW
stocks logo

TRAW

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
FY2025Q2
60.00K
+7.14%
--
--
60.00K
+7.14%
--
--
60.00K
+5.26%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Traws Pharma, Inc. (TRAW) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 31.84%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+31.84%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Traws Pharma Inc (TRAW.O) is -59.00, compared to its 5-year average forward P/E of -13.81. For a more detailed relative valuation and DCF analysis to assess Traws Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.81
Current PE
-59.00
Overvalued PE
34.99
Undervalued PE
-62.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.70
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.31
Undervalued EV/EBITDA
-3.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
181.92
Current PS
0.00
Overvalued PS
458.43
Undervalued PS
-94.59
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TRAW News & Events

Events Timeline

(ET)
2025-11-13
07:04:08
Traws Pharma Announces Q3 Earnings Per Share of 34 Cents Compared to a Loss of $1.49 Last Year
select
2025-10-14 (ET)
2025-10-14
07:07:59
Traws Pharma administers ratutrelvir to first patient in Phase 2 COVID trials
select
2025-08-18 (ET)
2025-08-18
07:03:07
Traws Pharma Granted Approval to Advance to Phase 2 COVID Research
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-03Benzinga
Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday

  • Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing Buy and Outperform ratings along with price targets.

  • Traws Pharma, Inc.: HC Wainwright & Co. analyst Brandon Folkes initiated coverage with a Buy rating and a price target of $8, while shares closed at $2.16.

  • Compass Therapeutics, Inc.: Canaccord Genuity analyst John Newman also initiated coverage with a Buy rating and a price target of $10, with shares closing at $5.22.

  • Linde plc and Others: CICC analyst Shanshan Shen rated Linde plc as Outperform with a price target of $510, and HC Wainwright initiated coverage on Pelthos Therapeutics and LifeSci Capital on Oculis Holding, both with positive ratings and significant price targets.

[object Object]
Preview
9.0
10-30PRnewswire
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

  • Collaboration Announcement: ChemDiv has extended its collaboration with Traws Pharma to support the clinical development of ratutrelvir, an oral antiviral treatment for COVID-19, which is currently in Phase 2 studies.

  • Drug Development Details: Ratutrelvir is a ritonavir-free Mpro inhibitor designed to be effective against various SARS-CoV-2 strains, featuring a simplified 10-day treatment regimen and avoiding drug-drug interactions.

  • Support Services: ChemDiv's ongoing support includes CMC process research, medicinal chemistry, translational pharmacology, and clinical pharmacology consulting to ensure successful clinical execution and regulatory submission.

  • Expert Systems' Role: Expert Systems is extending its contract with Traws Pharma to provide predictive safety pharmacology support, leveraging AI tools to enhance the clinical development of ratutrelvir.

[object Object]
Preview
9.0
10-23Newsfilter
Dover, Delaware -- Expert Systems Inc. Backs Traws Pharma's Phase 2 Clinical Trials for Ratutrelvir, an Innovative Ritonavir-Free Antiviral Treatment for COVID-19.

  • Expert Systems Supports Traws Pharma: Expert Systems Inc. is backing Traws Pharma as it begins Phase 2 clinical studies for Ratutrelvir (TRX01), an oral antiviral aimed at treating newly diagnosed COVID-19 patients.

  • Innovative Drug Design: Ratutrelvir is designed to be ritonavir-independent, enhancing its safety and efficacy by avoiding drug-drug interactions that affect many COVID patients, while demonstrating strong antiviral activity against various SARS-CoV-2 strains.

  • Phase 2 Clinical Trials: The Phase 2 program includes a non-inferiority trial against PAXLOVID® and a trial for patients ineligible for PAXLOVID®, addressing a critical need for effective treatments in underserved populations.

  • AI-Driven Development: Expert Systems utilizes AI and predictive pharmacology to optimize Ratutrelvir's pharmacokinetics and safety, aiming to provide a differentiated antiviral solution that targets both active infections and the prevention of viral rebound.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Traws Pharma Inc (TRAW) stock price today?

The current price of TRAW is 2.36 USD — it has increased 11.85 % in the last trading day.

arrow icon

What is Traws Pharma Inc (TRAW)'s business?

Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

arrow icon

What is the price predicton of TRAW Stock?

Wall Street analysts forecast TRAW stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRAW is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Traws Pharma Inc (TRAW)'s revenue for the last quarter?

Traws Pharma Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Traws Pharma Inc (TRAW)'s earnings per share (EPS) for the last quarter?

Traws Pharma Inc. EPS for the last quarter amounts to -0.34 USD, decreased -96.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for Traws Pharma Inc (TRAW)'s fundamentals?

The market is revising No Change the revenue expectations for Traws Pharma, Inc. (TRAW) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 31.84%.
arrow icon

How many employees does Traws Pharma Inc (TRAW). have?

Traws Pharma Inc (TRAW) has 7 emplpoyees as of December 05 2025.

arrow icon

What is Traws Pharma Inc (TRAW) market cap?

Today TRAW has the market capitalization of 18.92M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free